HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer
Tumors acquire numerous mutations during development and progression. When translated into proteins, these mutations give rise to neoantigens that can be recognized by T cells and generate antibodies, representing an exciting direction of cancer immunotherapy. While neoantigens have been reported in...
Main Authors: | Yingxue Ren, Yesesri Cherukuri, Daniel P. Wickland, Vivekananda Sarangi, Shulan Tian, Jodi M. Carter, Aaron S. Mansfield, Matthew S. Block, Mark E. Sherman, Keith L. Knutson, Yi Lin, Yan W. Asmann |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2020.1744947 |
Similar Items
-
Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations
by: Susumu Iiizumi, et al.
Published: (2019-02-01) -
Cancer neoantigen: Boosting immunotherapy
by: Peijia Xu, et al.
Published: (2020-11-01) -
Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy
by: Peipei Wang, et al.
Published: (2021-04-01) -
Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment
by: Alice Newey, et al.
Published: (2019-11-01) -
Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy
by: Daniel J. Verdon, et al.
Published: (2021-08-01)